TIC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. TIC is in a confirmed short-term downtrend (bearish MAs + falling MACD), with price sitting on first support (~10.10). While options positioning is aggressively bullish and analyst targets imply upside, the tape is still weak and there are no Intellectia buy signals today—so an impatient buyer is more likely to catch continued downside (next support ~9.67) than get an immediate rebound. Action: hold/avoid new buys at current levels.
Trend: Bearish. The moving average stack is negative (SMA_200 > SMA_20 > SMA_5), consistent with sustained selling pressure. Momentum: MACD histogram at -0.132 and negatively expanding, signaling downside momentum is strengthening rather than stabilizing. RSI: RSI_6 = 22.04, which is oversold and can precede bounces, but oversold alone is not a reversal signal when MACD and MAs are still bearish. Levels: Pivot 10.79 (key reclaim level). Immediate support S1 ~10.099 (price ~10.0–10.1 is sitting right on it); if it breaks, next support S2 ~9.672. Resistance levels: R1 11.482, R2 11.909. Pattern-based short-horizon bias (provided): ~60% chance of a small uptick next day (+0.43%), but bias turns negative over the next week (-0.89%), implying bounces may be short-lived.
Intellectia Proprietary Trading Signals
Analyst upside/catalyst narrative: JPMorgan initiated Overweight with $16 PT (~50% upside cited), highlighting non-discretionary services, cross-selling, and ~$25M cost synergy potential from integration (Acuren/NV5).
Margin improvement: Gross margin improved to 25.79% in 2025/Q3 (+25.01% YoY), supporting the synergy/efficiency story.
Options market positioning: Heavy call skew and elevated volume can support sharp rebound attempts if price stabilizes at support.
Earnings quality (latest quarter): Despite strong revenue growth, profitability is weak (net income and EPS negative), which can cap near-term upside.
Latest quarter: 2025/Q3. Revenue rose to 473,888,000 (+56.40% YoY), showing strong top-line momentum (likely helped by combination/integration effects). Profitability: Net income was -13,890,000 (down -83.83% YoY) and EPS was -0.08 (down -66.67% YoY), indicating profits have not yet caught up with revenue growth. Margins: Gross margin increased to 25.79 (+25.01% YoY), a constructive sign that integration/synergies may be improving unit economics, but the bottom line remains negative.
Recent rating/target trend: Mixed but improving overall due to new bullish initiations. JPMorgan (2026-01-09) initiated Overweight with $16 PT; Texas Capital (2025-11-20) initiated Buy with $17 PT; UBS (2025-11-14) lowered PT to $11.50 and kept Neutral. Wall Street pros: Clear synergy/cross-selling narrative, non-discretionary service exposure, and meaningful stated upside to PTs ($16–$17). Wall Street cons: Integration execution risk implied by prior PT cut/Neutral stance, and current weak profitability despite revenue growth. Influential/political flows: No recent congress trading data available; hedge fund and insider trend data are Neutral with no significant recent activity.
